thymia is a technology company.
thymia has raised $4.0M across 2 funding rounds.
Key people at thymia.
thymia has raised $4.0M in total across 2 funding rounds.
Key people at thymia.
thymia has raised $4.0M in total across 2 funding rounds.
thymia's investors include Calm/Storm Ventures, sequel, StartHer, Henrik Herr, Johann "Hansi" Hansmann, Omid Ashtari, Rosaleen Blair.
Thymia is a London-based health technology company founded in 2020 that develops AI-powered platforms to objectively measure and monitor mental health conditions, making mental health as trackable as physical metrics like blood pressure.[1][2] Its products, such as Helios for wellness (assessing burnout, stress, mental strain, tiredness, and confidence) and Apollo for clinical use (targeting depression, anxiety, ADHD; Apollo launching fully in 2025), serve healthcare providers, payers, employers, and wellness platforms globally across five continents.[1][2][5] By analyzing voice, video, facial expressions, movements, and behavioral data via gamified app-based activities, Thymia addresses the global mental health crisis—affecting over a billion people, with 75% lacking access—enabling efficient triaging, diagnosis, treatment, and early detection of issues like stress and burnout.[2][3][4] The company has shown strong growth, raising £2.7m in seed funding from Kodori Ventures and £1.1m via Crowdcube, expanding its data network toward half a billion patients, and earning recognition as a top London scaleup for 2025.[1][4]
Thymia was co-founded in 2020 in London by a team leveraging expertise in AI, machine learning, neuropsychology, and mental health, with key operations now spanning the UK, Greece (Athens office expansion), Europe, Canada, Latin America, India, and the US.[1][2] The idea emerged from the need to objectively assess mental health—starting with depression—using innovative digital biomarkers, inspired by the founders' recognition that over a billion people suffer from poor mental health without accessible measurement tools.[1][4] Early traction came swiftly: the startup secured £2.7m in seed funding led by Kodori Ventures, followed by £1.1m via Crowdcube, built an exclusive global dataset (the largest of its kind combining voice, video, and behavior), and rolled out products internationally by 2023, including AI platforms tested across cultures.[1][2][4] Pivotal moments include featuring in Sifted's reports on Greece's tech scene and City A.M.'s "10 London scaleups to watch in 2025," highlighting its rapid evolution into a multinational player.[1][4]
Thymia's standout advantages stem from its proprietary AI technology and global scalability:
Thymia rides the AI-in-healthcare wave, specifically the explosion in digital biomarkers and remote mental health monitoring, accelerated by post-pandemic awareness of the global mental health crisis (1B+ affected, 75% untreated).[2][4] Timing is ideal amid rising demand for scalable, objective tools amid clinician shortages and workplace wellness mandates, with market forces like AI advancements in multimodal data (voice/video/behavior) and regulatory nods for investigational devices favoring rapid adopters.[1][2] It influences the ecosystem by democratizing mental health data—expanding networks to represent diverse populations (e.g., via Greek engineering for global scale)—pushing competitors toward similar innovations and enabling payers/providers to cut costs via early intervention.[1][4] As part of London's thriving scaleup scene and Greece's emerging tech hub, Thymia amplifies Europe's healthtech footprint against US giants.[1][4]
Thymia is primed for explosive growth in 2025+, with Apollo's full clinical launch, Helios API expansions, and data network targeting half a billion patients via Athens scaling and global partnerships.[1][2] Trends like AI ethics regulations, workplace mental health mandates, and multimodal biomarkers will propel it, potentially unlocking Series A funding and pharma collaborations for drug trials.[2][4] Its influence could evolve from niche innovator to category leader, redefining mental health as quantifiable and proactive—echoing its mission to track state of mind like a thermometer, ultimately bridging the access gap for a billion people.[2]
thymia has raised $4.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $3.0M Seed | Calm/Storm Ventures, sequel, StartHer, Henrik Herr, Johann "Hansi" Hansmann, Omid Ashtari, Rosaleen Blair | |
| Jun 1, 2021 | $1.0M Seed | Calm/Storm Ventures, Henrik Herr, Johann "Hansi" Hansmann |
